Library / Sermorelin
Some human studies
Sermorelin
GHRH analogue · Growth hormone · GHRH (1-29), formerly Geref
What it is
The first 29 amino acids of natural growth hormone-releasing hormone, which carry its activity. It prompts the pituitary to release growth hormone.
What research covers
Was FDA-approved for diagnosing and treating growth hormone deficiency in children, and was withdrawn from the US market in 2008 for commercial reasons. Evidence for use in healthy adults is limited.
Reported side effects
- Injection-site reactions
- Headache
- Flushing
- Dizziness
Not suitable for, or talk to a doctor first
- Active cancer
- Pituitary or hypothalamic disease
- Pregnancy
Legal status
| Australia | Not an approved medicine in Australia. Peptides like this are generally prescription-only (Schedule 4) and need a prescription to import. Check current rules with the TGA. |
|---|---|
| United States | Brand product discontinued. Available from compounding pharmacies with a prescription. |
| Sport | Prohibited by the World Anti-Doping Agency (WADA) at all times. |
Rules change. Check with the TGA (Australia), your local regulator, or WADA for sport.
Key references
- Thorner et al. Once-daily subcutaneous GHRH therapy accelerates growth in GH-deficient children. J Clin Endocrinol Metab, 1996.
General information, not advice. Talk to a qualified healthcare professional before starting, changing or stopping anything.